Theravance Biopharma, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
62.57 |
95.73 |
94.63 |
129.00 |
144.03 |
216.56 |
| Przychód Δ r/r |
0.00% |
53.00% |
-1.14% |
36.32% |
11.65% |
50.36% |
| Przychód (min) |
48.90 |
80.90 |
69.31 |
129.00 |
114.26 |
171.80 |
| Przychód (max) |
88.26 |
113.97 |
154.61 |
129.00 |
193.59 |
291.07 |
| EBITDA (średnia) |
-54.31 |
-83.09 |
-82.14 |
-111.98 |
-125.02 |
-187.98 |
| EBIT (średnia) |
-55.94 |
-85.59 |
-84.61 |
-115.34 |
-128.78 |
-193.62 |
| EBIT % |
-89.41% |
-89.41% |
-89.41% |
-89.41% |
-89.41% |
-89.41% |
| Zysk netto (średni) |
-58.33 |
18.42 |
-23.86 |
-4.31 |
-5.84 |
59.93 |
| Zysk netto % |
-93.23% |
19.24% |
-25.21% |
-3.34% |
-4.06% |
27.67% |
| EPS (średnia) |
-1.05 |
0.38 |
-0.47 |
-0.08 |
-0.12 |
1.23 |
| Liczba analityków (Przychody) |
3 |
4 |
5 |
4 |
2 |
3 |
| Liczba analityków (EPS) |
3 |
2 |
3 |
4 |
3 |
2 |
| symbol |
TBPH |
TBPH |
TBPH |
TBPH |
TBPH |
TBPH |